Filing Flows › Humacyte (HUMA) › Q1 2026
Humacyte (HUMA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Humacyte (HUMA) reported revenue of $495K for the first quarter 2026 (Q1 2026), -4% from a year earlier and +6% from the quarter before.
Humacyte, Q1 2026: revenue $495K (-4% year over year), net loss $17.6M, operating cash flow −$25.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $495K | +6% | -4% |
| Operating profit | −$28.9M | — | — |
| Net earnings | −$17.6M | — | -145% |
| Operating cash flow | −$25.1M | — | — |
What changed
Revenue was $495K in Q1 2026, down 4% year over year and up 6% from the previous quarter. Product was the largest line at 100% of revenue. Product and Service Other lost $368K year over year (down 99%), 1673% of the total change.
Operating costs exceeded revenue by $28.9M, an operating margin of -5845.5%. Total costs grew 24% against a revenue fall of 4%. The fastest-growing cost line was Cost of revenue (+1286%). The quarter ended with a net loss of $17.6M, narrower than the previous quarter's $24.8M loss. Non-operating items added $11.3M, -64% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$25.1M. Non-cash charges added back $1.3M of depreciation and $3.2M of share-based compensation. Working capital and other items used $12.0M. Capital expenditures of $175K exceeded it, leaving free cash flow of −$25.3M.
Questions
What was Humacyte's revenue in the first quarter 2026?
Humacyte (HUMA) reported revenue of $495K for the first quarter 2026 (Q1 2026), -4% from a year earlier and +6% from the quarter before.
Source: Humacyte 10-Q on SEC EDGAR.